Bio-Rad reports Q2 adjusted EPS $2.61, consensus $1.75

Reports Q2 revenue $651.6M, consensus $614.29M. Norman Schwartz, Bio-Rad’s (BIO) Chairman and Chief Executive Officer, stated: “In a highly dynamic environment, we delivered solid quarterly results, both in terms of revenue and operating margin, through focused execution and careful expense management. We also completed the acquisition of droplet digital PCR developer Stilla Technologies, effectively expanding our Droplet Digital PCR offering with the recent launch of our QX Continuum system complemented by the QX700 series of acquired instruments.”